Kerwin Diana, Abdelnour Carla, Caramelli Paulo, Ogunniyi Adesola, Shi Jiong, Zetterberg Henrik, Traber Martin
Kerwin Medical Center Dallas Texas USA.
Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya Barcelona Spain.
Alzheimers Dement (Amst). 2022 Jul 24;14(1):e12334. doi: 10.1002/dad2.12334. eCollection 2022.
Alzheimer's disease (AD) and other dementias are a global challenge. Early diagnosis is important to manage the disease. However, there are barriers to diagnosis that differ by region. Researchers from Brazil, China, Nigeria, Spain, and Sweden have identified key barriers to AD diagnosis in their countries. In Brazil, socioeconomic inequalities and poor recognition of dementia by physicians can prevent diagnosis. In China, a very large population and lack of physician training in dementia make diagnosis problematic. In Nigeria, socioeconomic inequalities and cultural stigma can stand in the way of diagnosis. In Spain, patient hesitancy and an overloaded health-care system are barriers to diagnosis. In Sweden, inconsistent use of biomarkers is a prominent barrier to diagnosis of AD. To support diagnosis, more focus is needed on education of patients and physicians, increased use of support services, and improved access to biomarkers to accurately diagnose AD.
阿尔茨海默病(AD)和其他痴呆症是一项全球性挑战。早期诊断对于疾病管理至关重要。然而,不同地区的诊断存在障碍。来自巴西、中国、尼日利亚、西班牙和瑞典的研究人员已经确定了各自国家AD诊断的关键障碍。在巴西,社会经济不平等以及医生对痴呆症认识不足会妨碍诊断。在中国,人口众多以及医生缺乏痴呆症培训使得诊断存在问题。在尼日利亚,社会经济不平等和文化污名会阻碍诊断。在西班牙,患者的犹豫以及医疗系统负担过重是诊断的障碍。在瑞典,生物标志物使用不一致是AD诊断的一个突出障碍。为了支持诊断,需要更多地关注患者和医生的教育、增加支持服务的使用以及改善生物标志物的获取以准确诊断AD。